Rarity Bioscience

Rarity Biosciences is a biotechnology startup that operates in the field of cancer diagnostics. The company's primary product is the superRCA, a highly sensitive and specific molecular amplification technology. This technology is designed to detect rare nucleic acid sequences, such as cancer mutations, in biological samples like liquid biopsies. In simpler terms, it can find very small amounts of DNA changes that could indicate cancer in a patient's tissue or blood samples.

The superRCA technology is flexible and can be used in both research and clinical applications. It can detect multiple targets at once, a process known as multiplexing, making it a powerful tool for diagnosing cancer. The technology can be used in most hematology laboratories with existing equipment, making it more accessible and reducing response times for test results.

Rarity Biosciences serves a wide range of clients, including research institutions and clinical laboratories. The company's business model revolves around providing superRCA assays for research and service testing. Essentially, they make money by selling their technology and services to these institutions and laboratories.

The company was founded in 2021 as a spin-off from Uppsala University, with the aim of further developing and commercializing the superRCA technology. The technology was initially discovered and developed by PhD Lei Chen and Professor Ulf Landegren at the university's Department of Immunology, Genetics, and Pathology.

Keywords: Cancer Diagnostics, Molecular Amplification, superRCA Technology, Liquid Biopsies, Multiplexing, Hematology Laboratories, Research Institutions, Clinical Laboratories, Uppsala University, Biotechnology Startup.